METHOD DEVELOPMENT FOR THE DETERMINATION OF NIFEDIPINE IN HUMAN GINGIVAL CREVICULAR FLUID AND PLASMA BY HPLC


Dinçel A.

ISPBS-6 -THE SIXTH INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL AND BIOMEDICAL SCIENCES, Gaziantep, Turkey, 26 - 28 May 2022, vol.1, pp.70

  • Publication Type: Conference Paper / Summary Text
  • Volume: 1
  • City: Gaziantep
  • Country: Turkey
  • Page Numbers: pp.70
  • Lokman Hekim University Affiliated: Yes

Abstract

Abstract

One of the widely known side effects of nifedipine is gingival overgrowth. The aim of this study

is method development for determination of nifedipine concentration in gingival crevicular

fluid (GCF) and plasma by HPLC, and to determine whether there is a relationship between

plasma and GCF nifedipine levels.

Separation of nifedipine from GCF was performed by Microsphere, C18 (100 x 4.6 mm, particle

size 3 μm) analytical column and methanol, sodium acetate (pH=4.0, 10 mM) (60:40, v/v)

containing mobile phase at 0.8 ml/min. Detection of nifedipine and nitrendipine (internal

standard, 0.5 μg/ml) was performed by UV/Vis detector at 235 nm. GCF samples were

extracted by using a mixture of methanol and water (50:50, v/v). Plasma nifedipine content

were extracted by using a mixture of hexane and dichloromethane. The calibration curve for

nifedipine was linear over the concentration range of 0.01-0.5 μg/ml. The mean recovery (±SD)

from GCF was 99.05±3.72 % for nifedipine at a concentration of 0.1 μg/ml (n=6). The mean

recovery (±SD) from plasma was 102.03±5.62 % for nifedipine at a concentration of 0.1 μg/ml

(n=6).

No association was found between GCF and plasma levels, and nifedipine is not a risk factor

for gingival enlargement. Consequently, this study describes a simple, sensitive, and practical

HPLC-UV/Vis method which permits determination of nifedipine in human gingival crevicular

fluid and plasma samples.